1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease (American Trypanosomiasis) - Drugs In Development, 2022, provides an overview of the Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease (American Trypanosomiasis) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 1, 10, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 5 molecules, respectively.
Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chagas Disease (American Trypanosomiasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chagas Disease (American Trypanosomiasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chagas Disease (American Trypanosomiasis) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chagas Disease (American Trypanosomiasis) - Overview
- Chagas Disease (American Trypanosomiasis) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Cesa Alliance SA
- Collaborations Pharmaceuticals Inc
- ConserV Bioscience Ltd
- Daiichi Sankyo Co Ltd
- Diakonos Research Ltd
- Eisai Co Ltd
- GSK plc
- IC-MedTech Inc
- Novartis AG
- Oblita Therapeutics BVBA
- Sanofi
- Selva Therapeutics Inc
- Synstar Japan Co Ltd
- Chagas Disease (American Trypanosomiasis) - Drug Profiles
- (benznidazole + pyronaridine) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- (sodium ascorbate + menadione sodium bisulfite) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AP-3 - Drug Profile
- Product Description
- Mechanism Of Action
- chagas disease (bivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- chagas disease vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- chagas disease vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- Chagas disease vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- Chagas disease vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- Chagas disease vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Chagas disease vaccine 2 - Drug Profile
- Product Description
- Mechanism Of Action
- Cz-007 - Drug Profile
- Product Description
- Mechanism Of Action
- Cz-008 - Drug Profile
- Product Description
- Mechanism Of Action
- D-121 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DNDI-0690 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fexinidazole - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GNF-6702 - Drug Profile
- Product Description
- Mechanism Of Action
- K-777 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MAO-1 - Drug Profile
- Product Description
- Mechanism Of Action
- pyronaridine tetraphosphate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SLV-213 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for African Trypanosomiasis and Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Chagas Disease and Leishmaniasis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Infectious Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Protozoal Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CYP51A1 for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Pex14 for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
- Product Description
- Mechanism Of Action
- VNI - Drug Profile
- Product Description
- Mechanism Of Action
- Chagas Disease (American Trypanosomiasis) - Dormant Projects
- Chagas Disease (American Trypanosomiasis) - Discontinued Products
- Chagas Disease (American Trypanosomiasis) - Product Development Milestones
- Featured News & Press Releases
- Jun 01, 2019: Vaccine for prevention and treatment of Trypanosoma cruzi infection
- Jun 22, 2017: UTEP Scientists Awarded Patent for Chagas Disease Vaccine
- Aug 08, 2016: A single compound could treat three parasitic diseases
- Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
- May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world
- Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Chagas Disease (American Trypanosomiasis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Cesa Alliance SA, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Collaborations Pharmaceuticals Inc, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by ConserV Bioscience Ltd, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Co Ltd, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Diakonos Research Ltd, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by GSK plc, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by IC-MedTech Inc, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Selva Therapeutics Inc, 2022
- Chagas Disease (American Trypanosomiasis) - Pipeline by Synstar Japan Co Ltd, 2022
- Chagas Disease (American Trypanosomiasis) - Dormant Projects, 2022
- Chagas Disease (American Trypanosomiasis) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Chagas Disease (American Trypanosomiasis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Cesa Alliance SA
- Collaborations Pharmaceuticals Inc
- ConserV Bioscience Ltd
- Daiichi Sankyo Co Ltd
- Diakonos Research Ltd
- Eisai Co Ltd
- GSK plc
- IC-MedTech Inc
- Novartis AG
- Oblita Therapeutics BVBA
- Sanofi
- Selva Therapeutics Inc
- Synstar Japan Co Ltd
